World Library  
Flag as Inappropriate
Email this Article

Merotocin

Article Id: WHEBN0047062779
Reproduction Date:

Title: Merotocin  
Author: World Heritage Encyclopedia
Language: English
Subject: Lipo-oxytocin-1, Oxytocin, Oxytocin receptor agonists, Lactation failure, SRX246
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Merotocin

Merotocin
Systematic (IUPAC) name
(3R,6S,9S,12S,15S)-6-(2-Amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide
Identifiers
CAS Registry Number
ATC code None
PubChem CID:
ChemSpider
Synonyms N-(4-Sulfanylbutanoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-N-[(4-fluorophenyl)methyl]glycyl-L-leucylglycinamide cyclic (1-5)-thioether
Chemical data
Formula C48H68FN11O12S
Molecular mass 1042.183423 g/mol

Merotocin (INN) (developmental code name FE-202767), also known as carba-1-(4-FBzlGly7)dOT, is a potent (EC50 < 0.1 nM) and highly selective (>1000-fold over the related vasopressin receptors) peptidic agonist of the oxytocin receptor that was derived from oxytocin.[1][2][3] It is under development by Ferring Pharmaceuticals for the treatment of preterm mothers with lactation failure requiring lactation support, and is in phase II clinical trials for this indication.[3]

See also

References

  1. ^ Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G. (2012). "Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics". Journal of Neuroendocrinology 24 (4): 609–628.  
  2. ^ Yang, Yang; Li, Hao; Ward, Richard; Gao, Linghuan; Wei, Ji-Fu; Xu, Tian-Rui (2014). "Novel oxytocin receptor agonists and antagonists: a patent review (2002 – 2013)". Expert Opinion on Therapeutic Patents 24 (1): 29–46.  
  3. ^ a b Wiśniewski K, Alagarsamy S, Galyean R, Tariga H, Thompson D, Ly B, Wiśniewska H, Qi S, Croston G, Laporte R, Rivière PJ, Schteingart CD (2014). "New, potent, and selective peptidic oxytocin receptor agonists" (PDF). J. Med. Chem. 57 (12): 5306–17.  

External links

  • Pipeline - Ferring Pharmaceuticals
  • Merotocin - AdisInsight


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.